Photosensitizers in clinical PDT

Photodiagnosis and Photodynamic Therapy

Volumn 1, Issue 1, 2004, Pages 27-42

  Allison, Ron R ^a   Downie, Gordon H ^a   Cuenca, Rosa ^a   Hu, Xin Hua ^a,b   Childs, Carter J H ^a   Sibata, Claudio H ^a,b  

^a EAST CAROLINA UNIVERSITY   (United States)

^b EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Photodynamic therapy; Photosensitizers; Review

Indexed keywords

ALUMINUM PHTHALOCYANINE TETRASULFATE; AMINOLEVULINIC ACID; AMINOLEVULINIC ACID HEXYL ESTER; AMINOLEVULINIC ACID METHYL ESTER; BENZOPORPHYRIN DERIVATIVE; BENZVIX; DYE; GADOLINIUM TEXAPHYRIN; HEMATOPORPHYRIN; LUTETIUM TEXAPHYRIN; PHOTOCHLOR; PHOTOFRIN; PHOTOSENS; PHOTOSENSITIZING AGENT; PORPHYRIN; PURPURIN; TALAPORFIN; TEMOPORFIN; UNCLASSIFIED DRUG;

ACTINIC KERATOSIS; ARTERY DISEASE; BARRETT ESOPHAGUS; BASAL CELL CARCINOMA; BLADDER CARCINOMA; BLEACHING; BREAST CARCINOMA; CARDIOTOXICITY; CHOROID MELANOMA; CLINICAL TRIAL; DOSIMETRY; DRUG ACCUMULATION; DRUG BINDING; DRUG COST; DRUG MECHANISM; DRUG PENETRATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; FIBROSIS; FISTULA; FLUORESCENCE; HEART INFARCTION; HISTORY; HUMAN; HYDROPHOBICITY; HYPERTENSION; HYPOTENSION; LEUKOPLAKIA; LIGHT; LIGHT SCATTERING; NONHUMAN; PAIN; PARESTHESIA; PEER REVIEW; PHOTODYNAMIC THERAPY; PHOTOSENSITIVITY; PRIORITY JOURNAL; RASH; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SARCOMA; SKIN DEFECT; SKIN NECROSIS; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; STRUCTURE ANALYSIS; SUBRETINAL NEOVASCULARIZATION; SUNLIGHT; THORAX PAIN; VASCULARIZATION;

EID: 13644263744     PISSN: 15721000     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1572-1000(04)00007-9     Document Type: Article

References (148)

1. Allison R.R, Mang T.S, Wilson B.D. Photodynamic therapy for the treatment of nonmelanomatous cutaneous malignancies. Semin Cutan Med Surg. 17:(2):1998;153-163
2. Bonnett R, Berenbaum M. Porphyrins as photosensitizers. Ciba Found Symp. 146:1989;40-53. discussion 53-9
3. Dougherty TJ, Henderson BW, Schwartz S, et al. Historical perspective. In: Henderson BW, Dougherty TJ, editors. Photodynamic therapy. New York: Marcel Dekker; 1992. p. 1-15.
4. Finsen NF. Phototherapy. London: Arnold; 1901.
5. Raab O. On the effect of fluorescent substances on infusoria (in German). Z Biol. 39:1900;524
6. Jesionek A, Von Tappeiner H. On the treatment of skin cancers with fluorescent substances. Arch Klin Med. 82:1905;223-227
7. Jodlbauer A, Von Tappeiner H. On the participation of oxygen in the photodynamic effect of fluorescent substances. Münch Med Wochenschr. 52:1904;1139-1141
8. Von Tappeiner H, Joldlbauer A. On the effect of photodynamic (fluorescent) substances on protozoa and enzymes. Arch Klin Med. 80:1904;427-487
9. Schmid R. The porphyrias. In: Stanberg JB, Wyngaarden JB, Fredrickson DB, editors. The metabolic basis of inherited disease. New York: McGraw Hill Book Co; 1966. p. 813-70.
10. Dougherty T.J, Kaufman J.E, Goldfarb A, et al. Photoradiation therapy for the treatment of malignant tumors. Cancer Res. 38:(8):1978;2628-2635
11. Drabkin DL. Selected landmarks in the history of porphyrins and their biologically functional derivatives. In: Dolphin D, editor. The porphyrins. Academic Press; 1978. p. 31-84.
12. Konan Y.N, Gurny R, Allemann E. State of the art in the delivery of photosensitizers for photodynamic therapy. J Photochem Photobiol B. 66:(2):2002;89-106
13. Wagnieres G.A, Star W.M, Wilson B.C. In vivo fluorescence spectroscopy and imaging for oncological applications. Photochem Photobiol. 68:(5):1998;603-632
14. Gillenwater A, Jacob R, Richards-Kortum R. Fluorescence spectroscopy: a technique with potential to improve the early detection of aerodigestive tract neoplasia. Head Neck. 20:(6):1998;556-562
15. Svanberg K, af Klinteberg C, Nilsson A, et al. Laser-based spectroscopic methods in tissue characterization. Ann N Y Acad Sci. 838:1998;123-129
16. Richards-Kortum R, Sevick-Muraca E. Quantitative optical spectroscopy for tissue diagnosis. Annu Rev Phys Chem. 47:1996;555-606
17. Braichotte D.R, Savary J.F, Monnier P, et al. Optimizing light dosimetry in photodynamic therapy of early stage carcinomas of the esophagus using fluorescence spectroscopy. Lasers Surg Med. 19:(3):1996;340-346
18. Diamond K.R, Patterson M.S, Farrell T.J. Quantification of fluorophore concentration in tissue-simulating media by fluorescence measurements with a single optical fiber. Appl Opt. 42:2003;2436-2442
19. Hu XH, Feng Y, Lu JQ, et al. Modeling of type II photodynamic therapy process in a heteregeneous tissue phantom. Phys Med Biol 2004; submitted for publication.
20. Foster T.H, Murant R.S, Bryant R.G, et al. Oxygen consumption and diffusion effects in photodynamic therapy. Radiat Res. 126:(3):1991;296-303
21. Bonnett R, Berenbaum M.C. HpD - a study of its components and their properties. Adv Exp Med Biol. 160:1983;241-250
22. Mironov A.F, Nizhnik A.N, Nockel A.Y. Haematoporphyrin derivatives: an oligometric composition study. J Photochem Photobiol B: Biol. 4:1990;297-306
23. Kessel D, Thompson P, Musselman B, et al. Probing the structure and stability of the tumor-localizing derivative of hematoporphyrin by reductive cleavage with LiAlH4. Cancer Res. 47:(17):1987;4642-4645
24. Bonnett R, White R.D, Winfield U.J, et al. Hydroporphyrins of the meso-tetrahydroxyphenyl porphyrin series as tumors photosensitizers. Biochem J. 261:1989;277-280
25. Winkelman J.W, Collins G.H. Neurotoxicity of tetraphenylporphinesulfonate TPPS4 and its relation to photodynamic therapy. Photochem Photobiol. 46:(5):1987;801-807
26. Lapes M, Petera J, Jirsa M. Photodynamic therapy of cutaneous metastases of breast cancer after local application of meso-tetra-(para-sulphophenyl)- porphin (TPPS4). J Photochem Photobiol B. 36:(2):1996;205-207
27. Levy J.G, Waterfield E, Richter A.M, et al. Photodynamic therapy of malignancies with benzoporphyrin derivative monoacid ring A. Proc Soc Photo-Opt Instrum Eng. 2078:1994;99-101
28. Kennedy J.C, Pottier R.H. Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. J Photochem Photobiol B. 14:(4):1992;275-292
29. Hausman W. The photodynamic action of plant extracts containing chlorophyll. Biochem Z. 12:1907;331-334
30. Bonnett R. Photosensitizers of the porphyrin and phthalocyanine photodynamic therapy. Chem Soc Rev. 24:1995;19-33
31. Bonnett R. New photosensitizers for the photodynamic therapy of tumors. Proc Soc Photo-Opt Instrum Eng. 2078:1994;74-90
32. Roberts W.G, Shian F.Y, Nelson J.S, et al. In vitro characterization of monoaspartylchlorin e6 for photodynamic therapy. J Natl Cancer Inst. 80:1988;330-336
33. Allen R, Kessel D, Tharratt RS, et al. Photodynamic therapy of superficial malignancies with NPe6 in man. In: Spinelli P, DalFante M, Marchese R, editors. Photodynamic therapy and biomedical lasers. New York: Elsevier Science; 1992. p. 441-5.
34. Morgan A.R, Garbo G.M, Keck R.W, et al. New photosensitizers for photodynamic therapy: combined effect of metallopurpurin derivatives and light on transplantable bladder tumors. Cancer Res. 48:(1):1988;194-198
35. Moser J.G. Bacteriopheophorbide ester as a sensitizer. SPIE. 1881:1993;116-125
36. Stradnadko E.F, Skobelkin O.K, Vorozhtsov G.N, et al. Photodynamic therapy of cancer: five year clinical experience. Proc Soc Photo-Opt Instrum Eng. 3191:1997;253-262
37. Moser JG. 2nd and 3rd generation photosensitizers. Amsterdam: Harwood Academic Publishers; 1998.
38. Dougherty T.J. Studies on the structure of porphyrins contained in Photofrin II. Photochem Photobiol. 46:1987;569-573
39. Dougherty T.J. Photodynamic therapy. Photochem Photobiol. 58:(6):1993;895-900
40. Dougherty T.J, Gomer C.J, Henderson B.W, et al. Photodynamic therapy. J Natl Cancer Inst. 90:(12):1998;889-905
41. Sibata C.H, Colussi V.C, Oleinick N.L, et al. Photodynamic therapy: a new concept in medical treatment. Braz J Med Biol Res. 33:(8):2000;869-880
42. Bernstein Z.P, Wilson B.D, Oseroff A.R, et al. Photofrin photodynamic therapy for treatment of AIDS-related cutaneous Kaposi's sarcoma. AIDS. 13:(13):1999;1697-1704
43. Jones C.M, Mang T, Cooper M, et al. Photodynamic therapy in the treatment of Bowen's disease. J Am Acad Dermatol. 27:(6 Pt 1):1992;979-982
44. Taber S.W, Fingar V.H, Wieman T.J. Photodynamic therapy for palliation of chest wall recurrence in patients with breast cancer. J Surg Oncol. 68:(4):1998;209-214
45. Allison R, Mang T, Hewson G, et al. Photodynamic therapy for chest wall progression from breast carcinoma is an underutilized treatment modality. Cancer. 91:(1):2001;1-8
46. Moghissi K, Dixon K, Stringer M, et al. The place of bronchoscopic photodynamic therapy in advanced unresectable lung cancer: experience of 100 cases. Eur J Cardiothorac Surg. 15:(1):1999;1-6
47. Moghissi K, Dixon K, Hudson E, et al. Endoscopic laser therapy in malignant tracheobronchial obstruction using sequential Nd YAG laser and photodynamic therapy. Thorax. 52:(3):1997;281-283
48. Kato H, Okunaka T, Konaka C. Photodynamic therapy for bronchogenic carcinoma. Nippon Geka Gakkai Zasshi. 98:(1):1997;36-40
49. Cortese D.A, Edell E.S, Kinsey J.H. Photodynamic therapy for early stage squamous cell carcinoma of the lung. Mayo Clin Proc. 72:(7):1997;595-602
50. Pass H.I, Temeck B.K, Kranda K, et al. Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma. Ann Surg Oncol. 4:(8):1997;628-633
51. Savary J.F, Grosjean P, Monnier P, et al. Photodynamic therapy of early squamous cell carcinomas of the esophagus: a review of 31 cases. Endoscopy. 30:(3):1998;258-265
52. Grosjean P, Wagnieres G, Fontolliet C, et al. Clinical photodynamic therapy for superficial cancer in the oesophagus and the bronchi: 514 nm compared with 630 nm light irradiation after sensitization with Photofrin II. Br J Cancer. 77:(11):1998;1989-1995
53. Lightdale C.J, Heier S.K, Marcon N.E, et al. Photodynamic therapy with porfimer sodium versus thermal ablation therapy with Nd: YAG laser for palliation of esophageal cancer: a multicenter randomized trial. Gastrointest Endosc. 42:(6):1995;507-512
54. Overholt B.F, Panjehpour M. Photodynamic therapy in the management of Barrett's esophagus with dysplasia. J Gastrointest Surg. 4:(2):2000;129-130
55. Panjehpour M, Overholt B.F, Haydek J.M, et al. Results of photodynamic therapy for ablation of dysplasia and early cancer in Barrett's esophagus and effect of oral steroids on stricture formation. Am J Gastroenterol. 95:(9):2000;2177-2184
56. Overholt B.F, Panjehpour M. Photodynamic therapy in Barrett's esophagus. J Clin Laser Med Surg. 14:(5):1996;245-249
57. Overholt B.F, Panjehpour M, Haydek J.M. Photodynamic therapy for Barrett's esophagus: follow-up in 100 patients. Gastrointest Endosc. 49:(1):1999;1-7
58. Runfola M.A, Weber T.K, Rodriguez-Bigas M.A, et al. Photodynamic therapy for residual neoplasms of the perianal skin. Dis Colon Rectum. 43:(4):2000;499-502
59. Loh C.S, Bliss P, Bown S.G, et al. Photodynamic therapy for villous adenomas of the colon and rectum. Endoscopy. 26:(2):1994;243-246
60. Kostron H, Obwegeser A, Jakober R. Photodynamic therapy in neurosurgery: a review. J Photochem Photobiol B. 36:(2):1996;157-168
61. Muller P.J, Wilson B.C. Photodynamic therapy for recurrent supratentorial gliomas. Semin Surg Oncol. 11:(5):1995;346-354
62. Popovic E.A, Kaye A.H, Hill J.S. Photodynamic therapy of brain tumors. J Clin Laser Med Surg. 14:(5):1996;251-261
63. Biel M.A. Photodynamic therapy and the treatment of head and neck neoplasia. Laryngoscope. 108:(9):1998;1259-1268
64. Nseyo U.O, DeHaven J, Dougherty T.J, et al. Photodynamic therapy (PDT) in the treatment of patients with resistant superficial bladder cancer: a long-term experience. J Clin Laser Med Surg. 16:(1):1998;61-68
65. Cuenca R, Allison R, Downie G, et al. Breast cancer with chest wall progression: treating with photodynamic therapy. Ann Surg Oncol 2004; in press.
66. Peng Q, Warloe T, Berg K, et al. 5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges. Cancer. 79:(12):1997;2282- 2308
67. Loh C.S, MacRobert A.J, Bedwell J, et al. Oral versus intravenous administration of 5-aminolaevulinic acid for photodynamic therapy. Br J Cancer. 68:(1):1993;41-51
68. Peng Q, Berg K, Moan J, et al. 5-Aminolevulinic acid-based photodynamic therapy: principles and experimental research. Photochem Photobiol. 65:(2):1997;235-251
69. Wang I, Bendsoe N, Klinteberg C.A, et al. Photodynamic therapy vs. cryosurgery of basal cell carcinomas: results of a phase III clinical trial. Br J Dermatol. 144:(4):2001;832-840
70. Morton C.A, Whitehurst C, McColl J.H, et al. Photodynamic therapy for large or multiple patches of Bowen disease and basal cell carcinoma. Arch Dermatol. 137:(3):2001;319-324
71. Grant W.E, Hopper C, Macrobert A.J. Photodynamic therapy of oral cancer: photosensitization with systemic aminolevulinic acid. Lancet. 342:1993;147-148
72. Fan K.F, Hopper C, Speight P.M, et al. Photodynamic therapy using 5-aminolevulinic acid for premalignant and malignant lesions of the oral cavity. Cancer. 78:(7):1996;1374-1383
73. Kriegmair M, Waidelich R, Baumgartner R, et al. Photodynamic therapy of superficial bladder cancer. An alternative to radical cystectomy? Urologe A. 33:(4):1994;276-280
74. Waidelich R, Beyer W, Knuchel R, et al. Whole bladder PDT with 5-ALA and a white light source. Urology. 61:2003;332-337
75. Freeman M, Vinciullo C, Francis D, et al. A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix) with single cycle cryotherapy in patients with actinic keratosis: a prospective, randomized study. J Dermatolog Treat. 14:(2):2003;99-106
76. Pariser D.M, Lowe N.J, Stewart D.M, et al. Photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: results of a prospective randomized multicenter trial. J Am Acad Dermatol. 48:(2):2003;227-232
77. Ca M. Methyl aminolevulinate (Metvix) photodynamic therapy - practical pearls. J Dermatolog Treat. 14:(Suppl 3):2003;23-26
78. Lange N, Jichlinski P, Zellweger M, et al. Photodetection of early human bladder cancer based on the fluorescence of 5-aminolaevulinic acid hexylester-induced protoporphyrin IX: a pilot study. Br J Cancer. 80:(1/2):1999;185-193
79. Jichlinski P, Guillou L, Karlsen S.J, et al. Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer - a multicenter study. J Urol. 170:(1):2003;226-229
80. Gossner L, Sroka R, Hahn E.G, et al. Photodynamic therapy: successful destruction of gastrointestinal cancer after oral administration of aminolevulinic acid. Gastrointest Endosc. 41:(1):1995;55-58
81. Mlkvy P, Messmann H, Regula J, et al. Sensitization and photodynamic therapy (PDT) of gastrointestinal tumors with 5-aminolaevulinic acid (ALA) induced protoporphyrin IX (PPIX). A pilot study. Neoplasma. 42:(3):1995;109-113
82. Ackroyd R, Kelty C.J, Brown N.J, et al. Eradication of dysplastic Barrett's oesophagus using photodynamic therapy: long-term follow-up. Endoscopy. 35:(6):2003;496-501
83. Ortner M.A, Zumbusch K, Liebetruth J, et al. Is topical delta-aminolevulinic acid adequate for photodynamic therapy in Barrett's esophagus? A pilot study. Endoscopy. 34:(8):2002;611-616
84. Regula J, MacRobert A.J, Gorchein A, et al. Photosensitisation and photodynamic therapy of oesophageal, duodenal, and colorectal tumours using 5 aminolaevulinic acid induced protoporphyrin IX - a pilot study. Gut. 36:(1):1995;67-75
85. Houle J.M, Strong A. Clinical pharmacokinetics of verteporfin. J Clin Pharmacol. 42:(5):2002;547-557
86. Houle J.M, Strong H.A. Duration of skin photosensitivity and incidence of photosensitivity reactions after administration of verteporfin. Retina. 22:(6):2002;691-697
87. Leung J. Photosensitizers in photodynamic therapy. Semin Oncol. 21:1994;4-10
88. Richter A.M, Kelly B, Chow J, et al. Preliminary studies on a more effective phototoxic agent than hematoporphyrin. J Natl Cancer Inst. 79:(6):1987;1327-1332
89. Gragoudas E, Schmidt-Erfurth U, Sickenkey M. Results and preliminary dosimetry of photodynamic therapy for choroidal neovascularization in age-related macular degeneration in a phase I/II study. Assoc Res Vision Opthamol. 38:1997;73
90. Blinder K.J, Blumenkranz M.S, Bressler N.M, et al. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial - VIP report no. 3. Ophthalmology. 110:(4):2003;667-673
91. Young L.H, Howard M.A, Hu L.K, et al. Photodynamic therapy of pigmented choroidal melanomas using a liposomal preparation of benzoporphyrin derivative. Arch Ophthalmol. 114:(2):1996;186-192
92. Barbazetto I.A, Lee T.C, Rollins I.S, et al. Treatment of choroidal melanoma using photodynamic therapy. Am J Ophthalmol. 135:(6):2003;898-899
93. Lui H. Photodynamic therapy in dermatology with porfimer sodium and benzoporphyrin derivative: an update. Semin Oncol. 21:(6 Suppl 15):1994;11-14
94. Sessler J.L, Miller R.A. Texaphyrins: new drugs with diverse clinical applications in radiation and photodynamic therapy. Biochem Pharmacol. 59:(7):2000;733-739
95. Young S.W, Woodburn K.W, Wright M, et al. Lutetium texaphyrin (PCI-0123): a near-infrared, water-soluble photosensitizer. Photochem Photobiol. 63:(6):1996;892-897
96. Sessler J.L, Hemmi G, Mody T.D, et al. Texaphyrins: synthesis and applications. Acc Chem Res. 27:1994;43-50
97. Young S.W, Woodburn K.W, Wright M, et al. Lutetium texaphyrin (PCI-0123): a near-infrared, water-soluble photosensitizer. Photochem Photobiol. 63:(6):1996;892-897
98. Carde P, Timmerman R, Mehta M.P, et al. Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases. J Clin Oncol. 19:(7):2001;2074-2083
99. Renschler MF, Yuen A, Panella TJ, et al. Photodynamic therapy trials with lutetium texaphyrin PCI-0123 (Lu-Tex). In: 25th Annual Meeting for Photobiology. St. Louis, MO: The American Society for Photobiology; 1997.
100. Renschler M.F, Yuen A.R, Panella T.J, et al. Photodynamic therapy trials with lutetium texaphyrin (Lu-Tex) in patients with locally recurrent breast cancer. Proc Soc Photo-Opt Instrum Eng. 3247:1998;35-39
101. Dimofte A, Zhu T.C, Hahn S.M, et al. In vivo light dosimetry for motexafin lutetium-mediated PDT of recurrent breast cancer. Lasers Surg Med. 31:(5):2002;305-312
102. Rockson S.G, Kramer P, Razavi M, et al. Photoangioplasty for human peripheral atherosclerosis: results of a phase I trial of photodynamic therapy with motexafin lutetium (Antrin). Circulation. 102:(19):2000;2322-2324
103. Kereiakes D.J, Szyniszewski A.M, Wahr D, et al. Phase I drug and light dose-escalation trial of motexafin lutetium and far red light activation (phototherapy) in subjects with coronary artery disease undergoing percutaneous coronary intervention and stent deployment: procedural and long-term results. Circulation. 108:(11):2003;1310-1315
104. Renschler M.F, Yuen A.R, Panella T.J. Photodynamic therapy trials with lutetium texaphyrin. Photochem Photobiol. 65:1997;475
105. Berenbaum M.C, Chevretton E.B, et al. Selectivity of meso- tetra(hydroxyphenyl) porphyrins and chlorins and of Photofrin II in causing photodamage in tumor, skin. Lasers Med Sci. 8:1993;235-243
106. Glanzmann T, Hadjur C, Zellweger M, et al. Pharmacokinetics of tetra(m-hydroxyphenyl)chlorin in human plasma and individualized light dosimetry in photodynamic therapy. Photochem Photobiol. 67:(5):1998;596-602
107. Kubler A.C, Haase T, Staff C, et al. Photodynamic therapy of primary nonmelanomatous skin tumours of the head and neck. Lasers Surg Med. 25:(1):1999;60-68
108. Baas P, Saarnak A.E, Oppelaar H, et al. Photodynamic therapy with meta-tetrahydroxyphenylchlorin for basal cell carcinoma: a phase I/II study. Br J Dermatol. 145:(1):2001;75-78
109. Kubler A.C, de Carpentier J, Hopper C, et al. Treatment of squamous cell carcinoma of the lip using Foscan-mediated photodynamic therapy. Int J Oral Maxillofac Surg. 30:(6):2001;504-509
110. Grosjean P, Savary J.F, Mizeret J, et al. Photodynamic therapy for cancer of the upper aerodigestive tract using tetra(m-hydroxyphenyl)chlorin. J Clin Laser Med Surg. 14:(5):1996;281-287
111. Friedberg J.S, Mick R, Stevenson J, et al. A phase I study of Foscan-mediated photodynamic therapy and surgery in patients with mesothelioma. Ann Thorac Surg. 75:(3):2003;952-959
112. Schouwink H, Rutgers E.T, van der Sijp J, et al. Intraoperative photodynamic therapy after pleuropneumonectomy in patients with malignant pleural mesothelioma: dose finding and toxicity results. Chest. 120:(4):2001;1167-1174
113. Ris H.B, Altermatt H.J, Nachbur B, et al. Intraoperative photodynamic therapy with m-tetrahydroxyphenylchlorin for chest malignancies. Lasers Surg Med. 18:(1):1996;39-45
114. Savary J.F, Monnier P, Fontolliet C, et al. Photodynamic therapy for early squamous cell carcinomas of the esophagus, bronchi, and mouth with m-tetra (hydroxyphenyl) chlorin. Arch Otolaryngol Head Neck Surg. 123:(2):1997;162-168
115. Etienne J, Dorme N, Bourg-Heckly G, et al. Local curative treatment of superficial adenocarcinoma in Barrett's esophagus. First results of photodynamic therapy with a new photosensitizer. Bull Acad Natl Med. 184:(8):2000;1731-1744. discussion 1744-7
116. Ell C, Gossner L, May A, et al. Photodynamic ablation of early cancers of the stomach by means of mTHPC and laser irradiation: preliminary clinical experience. Gut. 43:(3):1998;345-349
117. Mlkvy P, Messmann H, Pauer M, et al. Distribution and photodynamic effects of meso-tetrahydroxyphenylchlorin (mTHPC) in the pancreas and adjacent tissues in the Syrian golden hamster. Br J Cancer. 73:(12):1996;1473-1479
118. Bown S.G, Rogowska A.Z, Whitelaw D.E, et al. Photodynamic therapy for cancer of the pancreas. Gut. 50:(4):2002;549-557
119. Dilkes M.G, Benjamin E, Ovaisi S, et al. Treatment of primary mucosal head and neck squamous cell carcinoma using photodynamic therapy: results after 25 treated cases. J Laryngol Otol. 117:(9):2003;713-717
120. Fan K.F, Hopper C, Speight P.M, et al. Photodynamic therapy using mTHPC for malignant disease in the oral cavity. Int J Cancer. 73:(1):1997;25-32
121. Wenig B, D'Cruz A, Iqbal A, et al. Foscan-mediated photodynamic therapy in the palliative treatment of advanced head and neck cancer. In: Proceedings of the 39th American Society of Clinical Oncology. 2000.
122. Hornung R, Fehr M.K, Tromberg B.J, et al. Uptake of the photosensitizer benzoporphyrin derivative in human endometrium after topical application in vivo. J Am Assoc Gynecol Laparosc. 5:(4):1998;367-374
123. Suhr M.A, Hopper C, MacRobert A.J, et al. Clinical pilot study of interstitial photodynamic therapy for treatment of advanced head and neck tumors. Mund Kiefer Gesichtschir. 5:(5):2001;277-282
124. Copper M.P, Tan I.B, Oppelaar H, et al. Meta-tetra(hydroxyphenyl)chlorin photodynamic therapy in early-stage squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 129:(7):2003;709-711
125. Wyss P, Schwarz V, Dobler-Girdziunaite D, et al. Photodynamic therapy of locoregional breast cancer recurrences using a chlorin-type photosensitizer. Int J Cancer. 93:(5):2001;720-724
126. Patterson MS, Wilson BC. Photodynamic therapy. In: Dyh JV, editor. The modern technology of radiation oncology. Madison: Medical Physics Publishing; 1999. p. 941-80.
127. Grekin R, Razun N, Trommer R, et al. Tin ethyl etiopurpurin (SnET2) photodynamic therapy (PDT): results of a phase I/II clinical study conduced at UCSF for the treatment of AIDS-associted cutaneous Kaposi's sarcomas. In: International Conference on AIDS. 1996.
128. Mang T.S, Allison R, Hewson G, et al. A phase II/III clinical study of tin ethyl etiopurpurin (Purlytin)-induced photodynamic therapy for the treatment of recurrent cutaneous metastatic breast cancer. Cancer J Sci Am. 4:(6):1998;378-384
129. Kaplan M.J, Somers R.G, Greenberg R.H, et al. Photodynamic therapy in the management of metastatic cutaneous adenocarcinomas: case reports from phase 1/2 studies using tin ethyl etiopurpurin (SnET2). J Surg Oncol. 67:(2):1998;121-125
130. Razum N, Snyder A, Doiron D. SnET2: clinical update. Proc Soc Photo-Opt Instrum Eng. 2675:1996;43-46
131. Spikes J.D. Chlorins as photosensitizers in biology and medicine. J Photochem Photobiol B. 6:(3):1990;259-274
132. Kreimer-Birnbaum M. Modified porphyrins, chlorins, phthalocyanines, and purpurins: second-generation photosensitizers for photodynamic therapy. Semin Hematol. 26:(2):1989;157-173
133. Taber SW, Fingar VH, Coots CT, et al. Photodynamic therapy using mono-L-aspartyl chlorin e6 (NPe6) for the treatment of cutaneous disease: a phase I clinical study. Clin Cancer Res 1998;4(11):2741-6.
134. Lim JI. Photodynamic therapy for choroidal neovascular disease: photosensitizers and clinical trials. Ophthalmol Clin North Am 2002;15(4):473-8.
135. Furukawa K, Okunaka T, Tsuchida T, et al. A Phase I clinical study of photodynamic therapy of early stage lung carcinoma using ME2906 and a diode laser system. Porphyrins. 7:1998;199-206
136. Lustig R.A, Vogl T.J, Fromm D, et al. A multicenter Phase I safety study of intratumoral photoactivation of talaporfin sodium in patients with refractory solid tumors. Cancer. 98:(8):2003;1767-1771
137. Pandey R.K, Bellnier D.A, Smith K.M, et al. Chlorin and porphyrin derivatives as potential photosensitizers in photodynamic therapy. Photochem Photobiol. 53:(1):1991;65-72
138. Magne M.L, Rodriguez C.O, Autry S.A, et al. Photodynamic therapy of facial squamous cell carcinoma in cats using a new photosensitizer. Lasers Surg Med. 20:(2):1997;202-209
139. McCaw D.L, Pope E.R, Payne J.T, et al. Treatment of canine oral squamous cell carcinomas with photodynamic therapy. Br J Cancer. 82:(7):2000;1297-1299
140. Bellnier D.A, Greco W.R, Loewen G.M, et al. Population pharmacokinetics of the photodynamic therapy agent 2- [1-hexyloxyethyl]-2-devinyl pyropheophorbide-a in cancer patients. Cancer Res. 63:(8):2003;1806-1813
141. Ben-Hur E, Rosenthal I. The Phthalocyanines: a new class of mammalian cells photosensitizers with a potential for cancer phototherapy. Int J Radiat Biol Relat Stud Phys Chem Med. 47:(2):1985;145-147
142. Allen C.M, Sharman W.M, Van Lier J.E. Current Status of phthalocyanines in the photodynamic therapy of cancer. J Porphyrins Phthalocyanines. 5:2001;161-169
143. Peaston A.E, Leach M.W, Higgins R.J. Photodynamic therapy for nasal and aural squamous cell carcinoma in cats. J Am Vet Med Assoc. 202:(8):1993;1261- 1265
144. van Leengoed H.L, van der Veen N, Versteeg A.A, et al. Tumour tissue imaging using the localizing properties and fluorescence of some phthalocyanines. Int J Radiat Biol. 60:(1/2):1991;121-124
145. Uspenskii L.V, Chistov L.V, Kogan E.A, et al. Endobronchial laser therapy in complex preoperative preparation of patients with lung diseases. Khirurgiia (Mosk). 2:2000;38-40
146. Sokolov V.V, Stranadko E.F, Zharkova N.N, et al. The photodynamic therapy of malignant tumors in basic sites with the preparations photohem and photosens (the results of 3 years of observations). Vopr Onkol. 41:(2):1995;134-138
147. Stranadko E.F, Garbuzov M.I, Zenger V.G, et al. Photodynamic therapy of recurrent and residual oropharyngeal and laryngeal tumors. Vestn. Otorinolaringol. 3:2001;36-39
148. Ben-Hur E, Kol R, Marko R, et al. Combined action of phthalocyanine photosensitization and gamma-radiation on mammalian cells. Int J Radiat Biol. 54:(1):1988;21-30